



Express Mail No. EL 984898491 US

Deposited on: 12/05/2003

12-05-03

APPROVED

PTO DEPOSIT ACCOUNT CHARGE  
ACCOUNT # 34-1710

DUNLAP, CODDING &amp; ROGERS, P.C.

GP1643

PTO/SB/21 (08-00)

Approved for use through 10/31/2002. OMB 0651-0031  
U.S. Patent and Trademark Office: U.S. DEPARTMENT OF COMMERCE

<b>TRANSMITTAL FORM</b> (to be used for all correspondence after initial filing)	Application Number	10/022,066
	Filing Date	12/18/2001
	First Named Inventor	William H. Hildebrand
	Group Art Unit	1643
	Examiner Name	Not Yet Assigned
Total Number of Pages in This Submission	Attorney Docket Number	6680.034

ENCLOSURES (check all that apply)		
<input checked="" type="checkbox"/> Fee Transmittal Form <input type="checkbox"/> Fee Attached <input type="checkbox"/> Amendment / Reply <input type="checkbox"/> After Final <input type="checkbox"/> Affidavits/declaration(s) <input type="checkbox"/> Extension of Time Request <input type="checkbox"/> Express Abandonment Request <input checked="" type="checkbox"/> Information Disclosure Statement <input type="checkbox"/> Certified Copy of Priority Document(s) <input type="checkbox"/> Response to Missing Parts/Incomplete Application <input type="checkbox"/> Response to Missing Parts under 37 CFR 1.52 or 1.53	<input type="checkbox"/> Assignment Papers (for an Application) <input type="checkbox"/> Drawing(s) <input type="checkbox"/> Licensing-related Papers <input type="checkbox"/> Petition <input type="checkbox"/> Petition to Convert to a Provisional Application <input type="checkbox"/> Power of Attorney, Revocation Change of Correspondence Address <input type="checkbox"/> Terminal Disclaimer <input type="checkbox"/> Request for Refund <input type="checkbox"/> CD, Number of CD(s) _____	<input type="checkbox"/> After Allowance Communication to Group <input type="checkbox"/> Appeal Communication to Board of Appeals and Interferences <input type="checkbox"/> Appeal Communication to Group (Appeal Notice, Brief, Reply Brief) <input type="checkbox"/> Proprietary Information <input type="checkbox"/> Status Letter <input checked="" type="checkbox"/> Other Enclosure(s) (please identify below):  See remarks below:
<b>Remarks</b> 1. Transmittal Form (1 page); 2. Fee Transmittal (1 page); 3. Supplemental Information Disclosure Statement (3 pages); 4. Information Disclosure Statement By Applicant (formerly Form 1449) (5 pages); 5. Cited Materials; and 6. Postcard.		

SIGNATURE OF APPLICANT, ATTORNEY, OR AGENT		
Firm or Individual name	DUNLAP, CODDING & ROGERS, P.C., P.O. Box 16370, Customer Number 30589 Attn: Kathryn L. Hester, Ph.D., Reg. No. 46,768, Oklahoma City, Oklahoma 73113	
Signature		
Date	12-5-03	

CERTIFICATE OF MAILING			
I hereby certify that this correspondence is being deposited with the United States Postal Service with sufficient postage as first class mail or U.S. Express mail no. EL 984898491 US in an envelope addressed to the address below on this date: 12/05/2003			
Typed or printed name	Kathryn L. Hester, Ph.D.		
Signature		Date	12-5-03

SEND TO: Mail Stop - IDS  
COMMISSIONER FOR PATENTS  
P.O. Box 1450, Alexandria, VA 22313-1450

APPROVED

Express Mail No.: EL 984898491 US  
Date Deposited: 12/05/2003PTO DEPOSIT RECEIPT  
RECEIVED

PTO/SB/17 (10-02)

Approved for use through 10/31/2002. OMB 0651-0032

U.S. Patent and Trademark Office; U.S. DEPARTMENT OF COMMERCE  
DUNLAP, CODDING & ROGERS, P.C.**FEE TRANSMITTAL  
for FY 2003**

Patent fees are subject to annual revision.

☐ Applicant claims small entity status. See 37 CFR 1.27

TOTAL AMOUNT OF PAYMENT (\$ ) 0

**Complete if Known**

Application Number	10/022.066
Filing Date	12/18/2001
First Named Inventor	William H. Hildebrand
Examiner Name	Not Yet Assigned
Art Unit	1643
Attorney Docket No.	6680.034

**METHOD OF PAYMENT (check all that apply)**☐ Check ☐ Credit card ☐ Money Order ☐ Other ☐ None☒ Deposit Account:Deposit Account Number  
Deposit Account Name

04-1700

Dunlap, Coddling & Rogers, P.C.  
Customer No. 30589

The Commissioner is authorized to: (check all that apply)

☒ Charge fee(s) indicated below ☒ Credit any overpayments☒ Charge any additional fee(s) during the pendency of this application☐ Charge fee(s) indicated below, except for the filing fee to the above-identified deposit account.**FEE CALCULATION****1. BASIC FILING FEE**

Large Entity		Small Entity		Fee Description	Fee Paid
Fee Code	Fee (\$)	Fee Code	Fee (\$)		
1001	750	2001	375	Utility filing fee	
1002	330	2002	165	Design filing fee	
1003	520	2003	260	Plant filing fee	
1004	750	2004	375	Reissue filing fee	
1005	160	2005	80	Provisional filing fee	
<b>SUBTOTAL (1)</b>					<b>(\$ ) 0</b>

**2. EXTRA CLAIM FEES FOR UTILITY AND REISSUE**

Total Claims		Extra Claims		Fee from below		Fee Paid	
Independent Claims		** =		X		=	\$0
Multiple Dependent		** =		X		=	\$0

Large Entity		Small Entity		Fee Description	Fee Paid
Fee Code	Fee (\$)	Fee Code	Fee (\$)		
1202	18	2202	9	Claims in excess of 20	
1201	84	2201	42	Independent claims in excess of 3	
1203	280	2203	140	Multiple dependent claim, if not paid	
1204	84	2204	42	** Reissue independent claims over original patent	
1205	18	2205	9	** Reissue claims in excess of 20 and over original patent	
<b>SUBTOTAL (2)</b>					<b>(\$ ) 0</b>

\*\*or number previously paid, if greater; For Reissues, see above

**FEE CALCULATION (continued)****3. ADDITIONAL FEES**

Large Entity		Small Entity		Fee Description	Fee Paid
Fee Code	Fee (\$)	Fee Code	Fee (\$)		
1051	130	2051	65	Surcharge - late filing fee or oath	
1052	50	2052	25	Surcharge - late provisional filing fee or cover sheet	
1053	130	1053	130	Non-English specification	
1812	2,520	1812	2,520	For filing a request for <i>ex parte</i> reexamination	
1804	920*	1804	920*	Requesting publication of SIR prior to Examiner action	
1805	1,840*	1805	1,840*	Requesting publication of SIR after Examiner action	
1251	110	2251	55	Extension for reply within first month	
1252	410	2252	205	Extension for reply within second month	
1253	930	2253	465	Extension for reply within third month	
1254	1,450	2254	725	Extension for reply within fourth month	
1255	1,970	2255	985	Extension for reply within fifth month	
1401	320	2401	160	Notice of Appeal	
1402	320	2402	160	Filing a brief in support of an appeal	
1403	280	2403	140	Request for oral hearing	
1451	1,510	1451	1,510	Petition to institute a public use proceeding	
1452	110	2452	55	Petition to revive - unavoidable	
1453	1,300	2453	650	Petition to revive - unintentional	
1501	1,300	2501	650	Utility issue fee (or reissue)	
1502	470	2502	235	Design issue fee	
1503	630	2503	315	Plant issue fee	
1460	130	1460	130	Petitions to the Commissioner	
1807	50	1807	50	Processing fee under 37 CFR 1.17(q)	
1806	180	1806	180	Submission of Information Disclosure Stmt	
8021	40	8021	40	Recording each patent assignment per property (times number of properties)	
1809	750	2809	375	Filing a submission after final rejection (37 CFR 1.129(a))	
1810	750	2810	375	For each additional invention to be examined (37 CFR 1.129(b))	
1801	750	2801	375	Request for Continued Examination (RCE)	
1802	900	1802	900	Request for expedited examination of a design application	

Other fee (specify)

\*Reduced by Basic Filing Fee Paid

**SUBTOTAL (3)** (\$ ) 0**SUBMITTED BY**

(Complete if applicable)

Name (Print/Type)	Kathryn L. Hester, Ph.D.	Registration No. (Attorney/Agent)	46,768	Telephone	(405) 607-8600
Signature		Date	12/05/2003		

Mail Stop - IDS

Commissioner for Patents

SEND TO:

P.O. Box 1450, Alexandria, VA 22313-1450

**EXPRESS MAIL NO.: EL 984898491 US**  
**Deposited on: DECEMBER 5, 2003**

**PATENT**



**IN THE UNITED STATES PATENT AND TRADEMARK OFFICE**

Applicant: William H. Hildebrand et al. ) Atty. Dkt. No.: 6680.034  
Serial No.: 10/022,066 )  
Filed: December 18, 2001 )  
For: METHOD AND APPARATUS FOR THE )  
PRODUCTION OF SOLUBLE MHC )  
ANTIGENS AND USES THEREOF )

Mail Stop - IDS  
Commissioner for Patents  
P.O. Box 1450, Alexandria, VA 22313-1450

**SUPPLEMENTAL INFORMATION DISCLOSURE STATEMENT**

**List of Sections Forming Part of This  
Information Disclosure Statement**

The following sections are being submitted for this Information Disclosure Statement:

1. [X] Preliminary Statements
2. [X] FORM PTO/SB/08A AND 08B (formerly Form PTO-1449)
3. [X] Copies of Listed Information Items Accompanying this Statement
4. [X] Identification of Person(s) Making this Information Disclosure Statement

## **Section 1. Preliminary Statements**

Applicants submit herewith patents, publications or other information of which they are aware, which they believe may be material to the examination of this application and in respect of which there may be a duty to disclose.

The filing of this information disclosure statement shall not be construed as a representation that a search has been made (37 C.F.R. § 1.97(g)), an admission that the information cited is, or is considered to be, material to patentability or that no other material information exists.

The filing of this information disclosure statement shall not be construed as an admission against interest in any manner. Notice of January 9, 1992, 1135 O.G. 13-25, at 25.

## **Section 2. FORM PTO/SB/08A AND 08B (formerly Form PTO-1449)**

☒ [X] A completed FORM PTO/SB/08A AND 08B (formerly Form PTO-1449) is attached hereto.

## **Section 3. Copies of Listed Information Items Accompanying this Statement**


Legible copies of all items listed in FORM PTO/SB/08A AND 08B (formerly Form PTO-1449) accompany this information disclosure statement.

## **Section 4. Identification of Person(s) Making this SUPPLEMENTAL INFORMATION DISCLOSURE STATEMENT**

The person making this statement is the attorney/agent who signs below on the basis of the information:

- ☐ supplied by the inventor(s)
- ☐ supplied by an individual associated with the filing and prosecution of this application (37 C.F.R. § 1.56(c)).
- ☒ in the attorney/agent's file

Respectfully submitted,



---


Kathryn L. Hester, Ph.D., Reg. No. 46,768  
DUNLAP, CODDING & ROGERS, P.C.  
P.O. Box 16370, Customer No. 30589  
Oklahoma City, Oklahoma 73113  
Telephone: 405/607-8600  
Facsimile: 405/607-8686

Agent for Applicants

Express Mail: EL 984898491 US  
 Date Deposited: DECEMBER 5, 2003

Substitute for form 1449A/PTO

# INFORMATION DISCLOSURE STATEMENT BY APPLICANT



(use as many sheets as necessary)

Complete if Known	
Application Number	10/022,066
Filing Date	12/18/2001
First Named Inventor	William H. Hildebrand
Group Art Unit	1643
Examiner Name	Not Yet Assigned
Attorney Docket Number	6680.034


## U. S. PATENT DOCUMENTS

EXAM INIT.	Cite No. 1	U.S. PATENT NUMBER Number	Kind Code <sup>2</sup> (if known)	Name of Patentee or Applicant of Cited Document	Date of Publication of Cited Document MM-DD-YYYY	Pages, Columns, Lines, Where Relevant Passages or Relevant Figures Appear
	1	4,683,202		Mullis	7/28/1987	
	2	5,256,541		Pouletty et al.	10/26/1993	
	3	5,270,169		Chang et al.	12/14/1993	
	4	5,292,641		Pouletty	3/8/1994	
	5	5,482,841		Buelow	1/09/1996	
	6	5,710,248		Grose	1/20/1998	
	7	5,750,367		Chan	5/12/1998	
	8	5,776,746		Denney, Jr.	7/7/1998	
	9	5,798,209		Chan	8/25/1998	
	10	6,001,365		Peterson et al.	12/14/1999	
	11	6,255,073		Cai et al.	7/3/2001	


## FOREIGN PATENT DOCUMENTS

EXAM INIT.	Cite No. 1	Foreign Patent Document		Name of Patentee or Applicant of Cited Document	Date of Publication of Cited Document MM-DD-YYYY	Pages, Columns, Lines Where Relevant Passages or Relevant Figures Appear	T <sup>6</sup>
		Office 3	Number 4	Kind Code <sup>5</sup> (if known)			
	A		WO 95/11702		5/4/1995		
	B		WO 97/46256		12/11/1997		
	C		WO 98/06749		2/19/1998		
	D		WO 00/23053		4/27/2000		

**U.S. and Foreign:** <sup>1</sup>Unique citation designation number. <sup>2</sup>See attached Kinds of U.S. Patent Documents. <sup>3</sup>Enter Office that issued the document, by the two-letter code (WIPO Standard St.3). <sup>4</sup>For Japanese patent documents, the indication of the year of the reign of the Emperor must precede the serial number of the patent document. <sup>5</sup>Kind of document by the appropriate symbols as indicated on the document under WIPO Standard St. 16 if possible. <sup>6</sup>Applicant is to place a check mark here if English language Translation is attached.




EXAM INIT.		<h1>NON PATENT DOCUMENTS</h1> <p>Include name of the author (in CAPITAL LETTERS), title of the article (when appropriate), title of the item (book magazine, journal, serial, symposium, catalog, etc.), date, page(s), volume-issue number(s), publisher, city and/or country where published</p>
	AA	"MOLECULAR CLONING A LABORATORY MANUAL", Maniatis et al., Selected Text "RNA -Dependent DNA Polymerase" p.129, "Isolation of mRNA from Mammalian Cells" pp. 191-193, Cold Harbor Spring Laboratory (1982).
	BB	"LARGE SCALE PRODUCTION OF MURINE MONOCLONAL ANTIBODIES USING HOLLOW FIBER BIOREACTORS", Evans et al., BioTechniques, 6(8):763-767 (1988).
	CC	"HIV-1 REVERSE TRANSCRIPTASE IS A TARGET FOR CYTOTOXIC T LYMPHOCYTES IN INFECTED INDIVIDUALS", Walker et al., Science, 240(4848):64-66 (1988).
	DD	"ASSEMBLY OF MHC CLASS I MOLECULES ANALYZED IN VITRO", Townsend et al., Cell, 62(6):285-295 (1990).
	EE	"ALLELE-SPECIFIC MOTIFS REVEALED BY SEQUENCING OF SELF-PEPTIDES ELUTED FROM MHC MOLECULES", Falk et al., Nature, 351(6324):290-296, (1991).
	FF	"CHARACTERIZATION OF PEPTIDES BOUND TO THE CLASS I MHC MOLECULE HLA-A2.1 BY MASS SPECTROMETRY", Hunt et al., Science, 255(5049):1261-1263 (1992).
	GG	"PEPTIDE BINDING TO HLA-A2 AND HLA-B27 ISOLATED FROM ESCHERICHIA COLI", Parker et al., The Journal of Biological Chemistry, 267(8):5451-5459 (1992).
	HH	"ENDOGENOUS PEPTIDES OF SOLUBLE MAJOR HISTOCOMPATIBILITY COMPLEX CLASS I MOLECULE, H-2Lds: SEQUENCE MOTIF, QUANTITATIVE BINDING, AND MOLECULAR MODELING OF THE COMPLEX", Corr et al., J. Exp. Med., 176(6):1681-1692 (1992).
	II	"THE SPECIFICITY AND EFFICIENCY OF ENDOGENOUS PEPTIDES IN THE INDUCTION OF HLA CLASS I ALPHA CHAIN REFOLDING", Tanigaki, Eur J. Immunol., 22(8):2177-2180 (1992).
	JJ	"CAN ONE PREDICT ANTIGENIC PEPTIDES FOR MHC CLASS I-RESTRICTED CYTOTOXIC T LYMPHOCYTES USEFUL FOR VACCINATION?", Calin-Laurens et al., Vaccine, 11(9): 974-978 (1993).
	KK	"DIRECT IDENTIFICATION OF AN ENDOGENOUS PEPTIDE RECOGNIZED BY MULTIPLE HLA-A2.1-SPECIFIC CYTOTOXIC T CELLS", Henderson et al., Proc. Natl. Acad. Sci. USA, 90:10275-10279 (1993).
	LL	"CHARACTERIZATION OF ENDOGENOUS PEPTIDES ELUTED FROM THE CLASS I MHC MOLECULE HLA-B7 DETERMINED BY MASS SPECTROMETRY AND COMPUTER MODELING", Huczko et al., J. Immunol., 151(5):2572-2587 (1993).
	MM	"FLOW-CYTOMETRIC DETERMINATION OF PEPTIDE-CLASS I COMPLEX FORMATION IDENTIFICATION OF p53 PEPTIDES THAT BIND TO HLA-A2", Zeh et al., Human Immunology, 39:79-86 (1994).
	NN	"PEPTIDE BINDING TO THE MOST FREQUENT HLA-A CLASS I ALLELES MEASURED BY QUANTITATIVE MOLECULAR BINDING ASSAYS", Sette et al., Molecular Immunology, 31(11): 813-822 (1994).
	OO	"BINDING OF A PEPTIDE ANTIGEN TO MULTIPLE HLA ALLELES ALLOWS DEFINITION OF AN A2-LIKE SUPERTYPE", del Guercio et al., J Immunol., 154(2):685-693 (1995).
	PP	"AN HLA CLASS I PEPTIDE-BINDING ASSAY BASED ON COMPETITION FOR BINDING TO CLASS I MOLECULES ON INTACT HUMAN B CELLS IDENTIFICATION OF CONSERVED HIV-1 POLYMERASE PEPTIDES BINDING TO HLA-A*0301", van der Burg et al., Human Immunology, 44:189-198 (1995).
	QQ	"MEASURING INTERACTIONS OF MHC CLASS I MOLECULES USING SURFACE PLASMON RESONANCE", Khilko et al., J. Immunol. Methods, 183(1):77-94 (1995).
	RR	"PEPTIDE MOTIFS OF HLA-B58, B60, B61, AND B62 MOLECULES", Falk et al., Immunogenetics, 41(2-3):165-168 (1995).
	SS	"AN EMPIRICAL METHOD FOR THE PREDICTION OF T-CELL EPITOPES", Davenport et al., Immunogenetics, 42(5):392-397 (1995).
	TT	"PEPTIDE MOTIFS OF HLA-B38 AND B39 MOLECULES", Falk et al., Immunogenetics, 41(2-3):162-164, (1995).
	UU	"DETAILED MOTIFS FOR PEPTIDE BINDING TO HLA-A*0201 DERIVED FROM LARGE RANDOM SETS OF PEPTIDES USING CELLULAR BINDING ASSAY", Driifhout et al., Human Immunology, 43(1):1-12, (1995).



EXAM INIT.		<div>NON PATENT DOCUMENTS</div> <p>Include name of the author (in CAPITAL LETTERS), title of the article (when appropriate), title of the item (book magazine, journal, serial, symposium, catalog, etc.), date, page(s), volume-issue number(s), publisher, city and/or country where published</p>
	VV	"ANALYSIS OF THE STRUCTURE OF NATURALLY PROCESSED PEPTIDES BOUND BY CLASS I AND CLASS II MAJOR HISTOCOMPATIBILITY COMPLEX MOLECULES", Appella et al., EXS., 73:105-119 (1995).
	WW	"MAPPING AND RANKING OF POTENTIAL CYTOTOXIC T EPITOPES IN THE p53 PROTEIN: EFFECT OF MUTATIONS AND POLYMORPHISM ON PEPTIDE BINDING TO PURIFIED AND REFOLDED HLA MOLECULES", Gnjatic et al., Eur. J. Immunol., 25(6):1638-1642 (1995).
	XX	"SIMPLIFIED HIGH-SENSITIVITY SEQUENCING OF A MAJOR HISTOCOMPATIBILITY COMPLEX CLASS I-ASSOCIATED IMMUNOREACTIVE PEPTIDE USING MATRIX-ASSISTED LASER DESORPTION/IONIZATION MASS SPECTROMETRY", Woods et al., 226(1):15-25 (1995).
	YY	"PROBING HLA-B7 CONFORMATIONAL SHIFTS INDUCED BY PEPTIDE-BINDING GROOVE MUTATIONS AND BOUND PEPTIDE WITH ANTI-HLA MONOCLONAL ANTIBODIES", Smith et al., 157(6):2470-2478 (1996).
	ZZ	"MASS SPECTROMETRY. IONIZATION METHODS AND INSTRUMENTATION", Chapman, Methods Mol Biol., 61:9-28 (1996).
	aa	"HLA ALLELE SELECTION FOR DESIGNING PEPTIDE VACCINES", Kamalakr et al, Genetic Analysis: Biomolecular Engineering, 13:81-86 (1996).
	ab	"CLASS I-RESTRICTED PRESENTATION OF AN HIV-1 gp41 EPITOPE CONTAINING AN N-LINKED GLYCOSYLATION SITE. IMPLICATIONS FOR THE MECHANISM OF PROCESSING OF VIRAL ENVELOPE PROTEINS", Ferris et al., J Immunol., 156(2):834-840 (1996).
	ac	"EVALUATION OF HOLLOW FIBER BIOREACTORS AS AN ALTERNATIVE TO MURINE ASCITES PRODUCTION FOR SMALL SCALE MONOCLONAL ANTIBODY PRODUCTION", Jackson et al., J. Immunol. Methods, 189(2):217-231 (1996).
	ad	"T-CELL EPITOPE DETERMINATION", Walden, Curr Opin Immunol., 8(1):68-74 (1996).
	ae	"LARGE-SCALE PRODUCTION OF CLASS I BOUND PEPTIDES: ASSIGNING A SIGNATURE TO HLA-B*1501", Prilliman et al., Immunogenetics, 45(6):379-385 (1997).
	af	"HLA CLASS I BINDING MOTIFS DERIVED FROM RANDOM PEPTIDE LIBRARIES DIFFER AT THE COOH TERMINUS FROM THOSE OF ELUTED PEPTIDES", Davenport et al., J. Exp. Med., 185(2): 367-371 (1997).
	ag	"STABILITY OF EMPTY AND PEPTIDE-LOADED CLASS II MAJOR HISTOCOMPATIBILITY COMPLEX MOLECULES AT NEUTRAL AND ENDOSOMAL pH: COMPARISON TO CLASS I PROTEINS", Reich et al., Proc. Natl. Acad. Sci. USA, 94:2495-2500 (1997).
	ah	"HUMAN PEPTIDE TRANSPORTER DEFICIENCY: IMPORTANCE OF HLA-B IN THE PRESENTATION OF TAP-INDEPENDENT EBV ANTIGENS", de la Salle et al., J. Immunol., 158(10):4555-4563 (1997).
	ai	"A NOVEL, HIGHLY EFFICIENT PEPTIDE-HLA CLASS I BINDING ASSAY USING UNFOLDED HEAVY CHAIN MOLECULES: IDENTIFICATION OF HIV-1 DERIVED PEPTIDES THAT BIND TO HLA-A*0201 AND HLA-A*0301", Tan et al., J. Immunol. Methods, 205(2): 201-209 (1997).
	aj	"LARGE-SCALE PRODUCTION OF CLASS I BOUND PEPTIDES: ASSIGNING A SIGNATURE TO HLA-B*1501", Prilliman et al., Immunogenetics, 45(6):379-385 (1997).
	ak	"SYNTHETIC PEPTIDES BASED ON CHLAMYDIA TRACHOMATIS ANTIGENS IDENTIFY CYTOTOXIC T LYMPHOCYTE RESPONSES IN SUBJECTS FROM A TRACHOMA-ENDEMIC POPULATION", Holland et al., Clin. Exp. Immunol., 107(1):44-49 (1997).
	al	"COMPLEXITY AMONG CONSTITUENTS OF THE HLA-B*1501 PEPTIDE MOTIF", Prilliman et al., Immunogenetics, 48:89-97 (1998).
	am	"A MICROCAPILLARY COLUMN SWITCHING HPLC- ELECTROSPRAY IONIZATION MS SYSTEM FOR THE DIRECT IDENTIFICATION OF PEPTIDES PRESENTED BY MAJOR HISTOCOMPATIBILITY COMPLEX CLASS I MOLECULES", van der Heeft et al., Anal. Chem., 70:3742-3751 (1998).
	an	"SYNTHETIC PEPTIDES OF HUMAN PAPILLOMAVIRUS TYPE 18 E6 HARBORING HLA-A2.1 MOTIF CAN INDUCE PEPTIDE-SPECIFIC CYTOTOXIC T-CELLS FROM PERIPHERAL BLOOD MONONUCLEAR CELLS OF HEALTHY DONORS", Yoon et al., Virus Research, 54:23-29 (1998).
	ao	"MHCPEP, A DATABASE OF MHC-BINDING PEPTIDES: UPDATE 1997", Brusica et al., Nucleic Acids Research, 26(1): 368-371 (1998).






EXAM INIT.	NON PATENT DOCUMENTS	
	Include name of the author (in CAPITAL LETTERS), title of the article (when appropriate), title of the item (book magazine, journal, serial, symposium, catalog, etc.), date, page(s), volume-issue number(s), publisher, city and/or country where published	
ap	"PREDICTION OF MHC CLASS II-BINDING PEPTIDES USING AN EVOLUTIONARY ALGORITHM AND ARTIFICIAL NEURAL NETWORK", Brusic et al., Bioinformatics, 14(2): 121-130 (1998).	
aq	"EFFICIENT GENERATION OF MAJOR HISTOCOMPATIBILITY COMPLEX CLASS I-PEPTIDE COMPLEXES USING SYNTHETIC PEPTIDE LIBRARIES", Stevens et al., The Journal of Biological Chemistry, 273(5):2874-2884 (1998).	
ar	"NEURAL NETWORK-BASED PREDICTION OF CANDIDATE T-CELL EPITOPES", Honeyman et al., Nat. Biotechnol., 16(10): 966-969 (1998).	
as	"DIRECT IDENTIFICATION OF MAJOR HISTOCOMPATIBILITY COMPLEX CLASS I-BOUND TUMOR-ASSOCIATED PEPTIDE ANTIGENS OF A RENAL CARCINOMA CELL LINE BY A NOVEL MASS SPECTROMETRIC METHOD", Flad et al., Cancer Research, 58(24):5803-5811 (1998).	
at	"STRUCTURE AND FUNCTION OF A MEMBRANE-BOUND MURINE MHC CLASS I MOLECULE", Celia et al., Proc. Natl. Acad. Sci. USA, 96:5634-5639 (1999).	
au	"IDENTIFICATION OF HLA-A3 AND -B7-RESTRICTED CTL RESPONSE TO HEPATITIS C VIRUS IN PATIENTS WITH ACUTE AND CHRONIC HEPATITIS C", Chang et al., J. Immunol., 162(2):1156-1164 (1999).	
av	"HLA-B15 PEPTIDE LIGANDS ARE PREFERENTIALLY ANCHORED AT THEIR C TERMINI", Prilliman et al., J. Immunol., 162(12):7277-7284 (1999).	
aw	"STRUCTURE AND FUNCTION OF A MEMBRANE-BOUND MURINE MHC CLASS I MOLECULE", Proc. Natl. Acad. Sci. USA, 96:5634-5639 (1999).	
ax	"ALPHA-2 DOMAIN POLYMORPHISM AND HLA CLASS I PEPTIDE LOADING", Prilliman et al., Tissue Antigens, 54(5):450-460 (1999).	
ay	"SYFPEITHI: A DATABASE FOR MHC LIGANDS AND PEPTIDE MOTIFS", Rammensee et al., Immunogenetics, 50:213-219 (1999).	
az	"PEPTIDE MOTIF OF THE CLASS I MOLECULE HLA-B*1503", Prilliman et al., Immunogenetics, 49:144-146 (1999).	
ba	"CLAD AGAINST ALL CLADES- CAN VACCINOMICS BUILD A WORLD HIV VACCINE?", Hollon, The Scientist, 14(18):1 (2000).	
bb	"HUMAN IMMUNOLOGY- 26 <sup>TH</sup> ANNUAL ASHI MEETING ABSTRACTS 2000", 61: Supplement 2 (2000).	
bc	"C-TERMINAL EPITOPE TAGGING FACILITATES COMPARATIVE LIGAND MAPPING FROM MHC CLASS I POSITIVE CELLS", Hickman et al., Human Immunology, 61:1339-1346 (2000).	
bd	"PRODUCTION AND APPLICATION OF INDIVIDUAL HLA PROTEIN", Hildebrand et al., Human Immunology, abstract, vol. 61, no. SUPPL 2, page S81 XP008007733 (2000).	
be	"FIMM, a database of functional molecular immunology", C Schonbach et al., Nucleic Acids Research, vol. 28, no. 1, January 2000 (2000-01), pages 222-224, XP002242984 Oxford, UK figure 1; table 1	
bf	"RAPID DETERMINATION OF HLA B*07 LIGANDS FROM THE WEST NILE VIRUS NY99 GENOME", De Groot et al., Emerging Infectious Diseases, 7(4):706-713 (2001).	
bg	"EXAMINATION OF POSSIBLE STRUCTURAL CONSTRAINTS OF MHC-BINDING PEPTIDES BY ASSESSMENT OF THEIR NATIVE STRUCTURE WITHIN THEIR SOURCE PROTEINS", Schueler-Furman et al., PROTEINS: Structure, Function, and Genetics, 45:47-54 (2001).	
bh	"USE OF FLUORESCENCE POLARIZATION TO MONITOR MHC-PEPTIDE INTERACTIONS IN SOLUTION", Dedier et al., Journal of Immunological Methods, 255:57-66 (2001).	
bi	"PEPTIDE/MHC MONOMERS CAN BE INSERTED INTO ARTIFICIAL LIPID BILAYERS AS ARTIFICIAL ANTIGEN PRESENTATION CONSTRUCTS", Jiang et al., Section of Transplantation Immunology, BMT Department, M.D. Anderson Cancer Center, Houston, Texas, Abstract # 2126 (2001).	
bj	"NEURAL NETWORK METHOD FOR PREDICTING PEPTIDES THAT BIND MAJOR HISTOCOMPATIBILITY COMPLEX MOLECULES", Gulukota et al., Methods Mol. Biol., 156:201-209 (2001).	

**Non Patent Documents:** <sup>1</sup> Unique citation designation number. <sup>2</sup> Applicant is to place a check mark here if English language Translation is attached.

Examiner Signature: \_\_\_\_\_ Date Considered: \_\_\_\_\_

EXA  
M  
INIT.

## NON PATENT DOCUMENTS

Include name of the author (in CAPITAL LETTERS), title of the article (when appropriate), title of the item (book magazine, journal, serial, symposium, catalog, etc.), date, page(s), volume-issue number(s), publisher, city and/or country where published

EXAMINER: Initial if citation considered, whether or not citation is in conformance and not considered. Include copy of this form with next communication to applicant. \*\*Place of Publication refers to name of publication in which the information was published.

6680034 - 1449.wpd